On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026.
Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Phase 3 trial, while general and administrative expense declined slightly to $4.3 million. Net loss widened to $14.0 million from $10.4 million.
Sagimet Biosciences ended the quarter with $257.6 million in cash, cash equivalents, and marketable securities following an April 2026 equity financing that raised $175.0 million in gross proceeds. Management expects that balance to fund operations through 2028, beyond both the Phase 3 data readout and a planned new drug application submission.
Sagimet’s cash runway also highlights the financial balancing act facing pre-commercial biotech companies as they fund late-stage clinical development. In our recent story, Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?, we examined how a strong balance sheet can help a clinical-stage company finance its pipeline while it works toward commercial opportunities.
Goldman Sees the U.S. Trial As a Poor Match for the China Data that Built the Bull Case
Goldman Sachs analyst Andrea Newkirk resumed coverage of Sagimet Biosciences Inc. on September 24, 2026, with a Sell rating and a $7 price target, implying meaningful downside from the stock’s $9.11 close that day. Newkirk argued that the market is overlooking asymmetric downside ahead of the 2027 readout of Sagimet’s Phase 3 AURORA trial, as its endpoints and younger, potentially less compliant U.S. adolescent patient population differ meaningfully from those in the earlier China study that investors have used to underwrite the stock.
The catalyst is denifanstat, an oral once daily FASN inhibitor being developed for moderate to severe acne that would be the first new oral acne treatment approved in more than 40 years if successful.
The Food and Drug Administration cleared the AURORA trial’s investigational new drug application on August 13, 2026, and enrollment of roughly 800 U.S. patients, including 450 adolescents, is expected to begin in the fourth quarter of 2026. Management intends to submit a new drug application immediately after the 12-week data readout.
Barclays and Cantor Say the China Data Actually De-Risks the U.S. Readout
Barclays upgraded Sagimet Biosciences Inc. to Overweight from Equal Weight on September 9, 2026, more than doubling its price target to $18 from $8, and argued the opposite of Goldman’s thesis: that positive acne data already generated in China de-risks rather than complicates the U.S. Phase 3 readout and could support a run-up into the data.
Cantor Fitzgerald initiated coverage the same day with an Overweight rating, valuing SGMT at $26 per share based on projected peak denifanstat revenue of $2.2 billion by 2037, and called the current share price a mispricing of that opportunity.
Sagimet’s decision in April 2026 to prioritize its dermatology program rather than spread spending across its broader pipeline is central to both firms’ bull cases.
Barclays argued the strategy minimizes spending while preserving a large long-term opportunity for denifanstat. The firm believes positive acne data in China de-risks the Phase 3 U.S. readout, expected by the end of 2027.
What The Smart Money Sees
Hedge fund ownership increased to 28 funds from 18 during the second quarter, with Woodline Partners tripling its position to three million shares worth $23.2 million.
Short interest eased to 10.26 million shares as of September 15, 2026, from 11.75 million a month earlier, though it remained elevated at 16.81% of the float.
Takeaway
Three firms looked at the same China acne data roughly within two weeks of each other. They offered opposing views about what it means for a U.S. trial that will not read out until 2027, leaving Sagimet Biosciences Inc. in a genuinely binary setup rather than a stock where Wall Street disagrees only at the margins.
With ample cash runway and a pivotal Phase 3 study ahead, the debate now centers on whether the China data strengthens or weakens confidence in the U.S. readout.
READ NEXT: Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold? and Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
Hedge Fund Resource Center